Down syndrome biomarker project Save

Date Added
June 25th, 2020
PRO Number
Pro00090922
Researcher
Eric Hamlett

List of Studies

Silhouette
Keywords
Alzheimers, Children's Health, Dementia
Summary

We are recruiting individuals between the ages of 6 months and 85 years of age that have Down syndrome along with their mothers and siblings.
Each participant will provide a blood sample during for research purposes aimed at identifying novel biomarkers for health.
We will also gather some basic health information about senses, habits, exercise level and smoking/vaping exposures.

Institution
MUSC
Recruitment Contact
Eric Hamlett
919 357 7543
hamlette@musc.edu

Long term health impacts of olfactory dysfunction Save

Date Added
June 17th, 2020
PRO Number
Pro00100591
Researcher
Rodney Schlosser

List of Studies


Profiles_link
Keywords
Alzheimers, Dementia, Geriatrics, Nose
Summary

Loss of smell may affect over 20% of the population, specifically among older age groups and can result in significant health impacts. Smell loss can substantially affect an individual's overall well-being and quality of life. The purpose of this study is to evaluate the impacts of smell loss on neurologic disease (such as Alzheimer's and dementia) and on the risk of death over a 10-year period. We hypothesize that decreased sense of smell is associated with development of neurodegenerative disease and mortality. Participants in this study will fill out an electronic questionnaire (about 30 minutes long) at study entry, and a shortened electronic questionnaire (about 15 minutes long) every year after that for 10 years. No in-person visits are needed.

Institution
MUSC
Recruitment Contact
Kristina Storck
(843) 792-9496
sinus-research@musc.edu

Alcohol Use Disorder as a risk for Alzheimer's Disease: Insights from functional connectome analysis Save

Date Added
February 18th, 2020
PRO Number
Pro00096201
Researcher
Jane Joseph

List of Studies


Profiles_link
Keywords
Alcohol, Alzheimers, Dementia, Non-interventional, Substance Use
Summary

Alcohol Use Disorder (AUD) is a risk factor for Alzheimer's Disease (AD), but more research is needed to identify the potential mechanisms underlying this risk. The present study will use fMRI to examine brain network profiles in mid-life AUD. The goal is to develop techniques to assess risk for Alzheimer's Disease and related dementias. Participation includes cognitive testing and MRI scanning.

Institution
MUSC
Recruitment Contact
Laura Lohnes
843-792-7709
lohnes@musc.edu

Effect of LY3154207 on Cognition in Mild-to-ModerateDementia Due to Lewy Body Dementia (LBD) Associated with Idiopathic Parkinson's Disease (PD) or Dementia with Lewy Bodies (DLB) Save

Date Added
November 13th, 2018
PRO Number
Pro00075666
Researcher
Federico Rodriguez-porcel

List of Studies

Silhouette
Keywords
Dementia, Parkinsons
Summary

Study I7S-MC-HBEH (HBEH) is a multicenter, randomized (i.e. study in which people are assigned at random (by chance alone) to receive one of several clinical interventions), double-blind (i.e., neither the participant nor the person evaluating for the study knows what group the participant has been assigned to), parallel-group (i.e., a type of study where two groups of treatments, A and B, are given so that one group receives only A while another group receives only B.), placebo-controlled (i.e. one group will receive the study drug and the other will receive a substance that has no therapeutic effect, also known as placebo), fixed-dosage (i.e., the dosage will not change during the course of the study), Phase 2a study (i.e., a trial with the objective of assessing what dose is more effective in treating symptoms.) comparing various dosages of LY3154207 administered orally once a day with placebo over 12 weeks in subjects with mild-to-moderate Parkinson disease dementia (PDD).

The study includes a Screening Period (Visits 1 to 2) of a minimum of 7 days and up to 14 days, a 14-day Pretreatment Period (Visits 2 to 3), a 12-week Treatment Period (Visits 3 to 11), and a 14-day Safety Follow-Up Period (Visit 12).

Your participation will last about 17-18 weeks.

The purpose of this study is to find out how LY3154207 compares with placebo in treating memory and thinking problems in individuals with mild-to-moderate Parkinson's disease dementia.

Institution
MUSC
Recruitment Contact
Timothy Sheehan
843-792-0372
sheehant@musc.edu

Using Connectomics to Characterize Risk for Alzheimer's Disease Save

Date Added
October 17th, 2017
PRO Number
Pro00071249
Researcher
Jane Joseph

List of Studies


Profiles_link
Keywords
Alzheimers, Dementia
Summary

This study will use neuroimaging to understand how the connections in the brain change in Alzheimer's Disease. Changes will also be examined in individuals with mild cognitive impairment and healthy aging. The goal is to discover which brain changes are present in healthy aging and MCI so that future studies can assess the risk for developing Alzheimer's Disease. The study involves blood draw, cognitive testing, MRI, PET scanning, and a 1-year follow-up visit to repeat cognitive testing and MRI scanning.

Institution
MUSC
Recruitment Contact
Laura Lohnes
8437927709
lohnes@musc.edu

Change_preferences

-- OR --

Create_login